Source comparison
Melanotan-1 Safe Long Term Use: Clinical Evidence Comparison
24 months EPP patients (n=94) Photoprotection efficacy Nausea (38%), flushing, headache; 1 case supraventricular tachycardia Blood pressure, ECG at baseline and every 6 months FDA/EMA approved for this duration in EPP only 12 months Healthy volunteers (Phase I
This comparison does not assign a generated winner or score.
- 24 months
- EPP patients (n=94)
- Photoprotection efficacy
- Nausea (38%), flushing, headache; 1 case supraventricular tachycardia
- Blood pressure, ECG at baseline and every 6 months
- FDA/EMA approved for this duration in EPP only
- 12 months
- Healthy volunteers (Phase I/II)
- Safety and pharmacokinetics
- Nausea (25%), skin darkening, mild GI discomfort
- Blood pressure monitoring; no significant changes detected
- Investigational use only
- >24 months
- No published human data
- N/A
- No long-term safety data available
- No formal cardiovascular outcome studies beyond 2 years
- Not evaluated by regulatory bodies
- Continuous/cosmetic use
- Off-label users (no controlled data)
- Anecdotal reports include persistent nausea, darkened nevi, unknown cardiovascular effects
- No systematic monitoring in place
- Not approved; sourcing often unregulated